MUB Medical Solutions Featured in Onsagers’ Insightful Article on Our IP Journey

We are proud to announce that MUB Medical Solutions has been highlighted by Onsagers in a detailed article focusing on our Intellectual Property (IP) strategy journey. This feature delves into the meticulous planning, strategic foresight, and collaborative efforts that have shaped our approach to IP management and protection.

In the article, Onsagers explores the steps MUB Medical has taken to navigate the complex world of patents and intellectual property rights. From initial concept to global market entry, our partnership with Onsagers has been instrumental in securing our innovations, ensuring they are fully protected and leveraged to their utmost potential.

This recognition is a testament to the innovative spirit and dedication of our team at MUB Medical Solutions. It underscores our commitment to advancing medical technology while safeguarding our contributions through effective IP strategy.

We invite our partners, clients, and the broader community to read this insightful article to understand the depth of our IP journey and how it supports our mission to innovate within the medical sector.

Learn for more about Scandinavian innovation with global IP protection



MUB Medical Joins EWMA

MUB Medical joins EWMA – European Wound Management Association

We are honored to announce that MUB Medical Solutions has become a proud member of the European Wound Management Association (EWMA), a distinguished not-for-profit organization dedicated to advancing wound care excellence across Europe and beyond.

EWMA, established in 1991 as a registered charity in the UK, serves as a unifying force, connecting national wound management organizations, individuals, and groups passionate about wound care. At the core of EWMA’s mission lies the commitment to promote interdisciplinary and cost-effective wound care of the highest quality.

As an active member of EWMA, MUB Medical Solutions is poised to leverage this invaluable network to further our mission of making wound closure accessible, affordable, and efficient for all. We eagerly anticipate the opportunity to collaborate with experts within the EWMA community, sharing insights and expertise about our innovative solution, Sutrips.

Through our partnership with EWMA, we aim to amplify awareness about Sutrips and its transformative impact on wound closure. Together, we can drive progress, raise standards in wound management, and contribute to a healthier and more informed healthcare landscape.

We express our heartfelt gratitude to EWMA for this collaboration and look forward to a fruitful and impactful journey ahead.

To learn more about EWMA and its mission, please visit the EWMA website.

To learn more about Sutrips, please visit MUB Medical and follow our LinkedIn page.


Pre-clinical Trials Completed

Pre-clinical Trials Completed

We are thrilled to share a momentous achievement in our ongoing journey to transform wound closure with Sutrips.

In our recent independent clinical trial, Sutrips underwent test against the conventional interrupted suture technique.

The results speak volumes, and we couldn’t be more excited to reveal our progress!

This milestone takes us one step closer to realizing our mission: making wound closure universally accessible, affordable, and efficient.

For those eager to delve deeper into the clinical trial findings, we invite you to explore the full report, available for download. Please Click here.

Stay tuned as we continue to pioneer innovation in wound closure for a healthier world.


MUB Medical Secures Funding for Pre-clinical Trials

MUB Medical Secures Funding for Pre-clinical Trials

We are thrilled to announce that MUB Medical has received financing from Innovation Norway to conduct pre-clinical trials for Sutrips. This marks the third time that Innovation Norway has supported us financially, and we are incredibly grateful for their ongoing trust and belief in our vision.
With the backing of Innovation Norway, we are now focused on preparing for Sutrips’ global market introduction. We will actively engage with key industry players to explore potential collaborations for the successful launch of Sutrips.
It’s an exhilarating time for us, and we invite you to follow us on LinkedIn for more exciting updates. Stay tuned as we share the remarkable results of our proof of concept, which we recently completed.
Thank you for your unwavering support and enthusiasm as we work towards revolutionizing wound care with Sutrips! A simple Scandinavian solution for a complex global problem.


Introducing Sutrips

Introducing Sutrips-
Wound Closure with Adjustable Tension

We are thrilled to unveil the much-anticipated product introduction video for Sutrips, our game-changing suture tool that is set to transform the field of wound closure.

Sutrips: Precision in Every Stitch

Sutrips is not just another ordinary suture tool. It’s a breakthrough innovation that empowers healthcare professionals to achieve exceptional wound closure results. With Sutrips, we have harnessed the power of adjustable tension, allowing for a new level of precision and control in each stitch.

Advanced Technology, Optimal Healing

By providing the ability to apply different tension to each stitch, Sutrips offers unparalleled versatility and customization. This means healthcare professionals can adapt the tension to suit the specific needs of each wound, ensuring optimal healing outcomes. Whether it’s a deep laceration, a delicate incision, or any other wound type, Sutrips enables precise tension application for superior results.

Innovation at Its Finest

Sutrips represents a significant leap forward in wound closure technology. It eliminates the limitations of traditional suture tools by integrating adjustable tension capabilities into a user-friendly, all-in-one device. This not only streamlines the suturing process but also enhances patient comfort and minimizes complications.

Empowering Healthcare Professionals, Elevating Patient Care

We are proud to equip healthcare professionals with the tools they need to deliver the highest standard of care. Sutrips empowers them to achieve remarkable results, reduce procedural time, and optimize the healing journey for their patients. By harnessing the power of adjustable tension, Sutrips paves the way for advancements in wound closure techniques and improved patient outcomes.

Join Us on the Journey

We invite you to watch our product introduction video to witness the groundbreaking capabilities of Sutrips. Together, let’s revolutionize wound closure and make a lasting impact on the healthcare industry. Like, comment, and share this post to spread the word and join us on this exciting journey!

Explore also about Patent Issued in Indonesia.


Patent Issued in Indonesia


Securing Patent in Indonesia

We are thrilled to announce that MUB Medical Solutions has successfully secured a patent for our innovative wound closure solution, Sutrips, in Indonesia. With a population of over 270 million, Indonesia represents a significant and promising market for our product.

The patent grant in Indonesia further strengthens our position and allows us, along with our esteemed partners, to enforce protection rights for the sales and distribution of Sutrips in this important market. This milestone achievement underscores our commitment to delivering cutting-edge solutions and protecting our intellectual property.

“We are delighted to receive the patent for Sutrips in Indonesia,” said Ubbat Ocak, Founder of MUB Medical Solutions. “This achievement solidifies our market presence in the region and enables us to bring our innovative wound closure technology to healthcare professionals and patients in Indonesia.”

The Indonesian market holds immense potential due to its large population and growing healthcare needs. The patent provides us with a strong foundation to establish partnerships, expand market reach, and cater to the demands of healthcare providers seeking advanced wound closure solutions.

“We recognize the significance of the Indonesian market and the opportunities it presents,” stated Yasar Shaikh, CEO of MUB Medical Solutions. “Securing the patent for Sutrips in Indonesia empowers us to deliver superior quality products while upholding our commitment to intellectual property rights and ensuring the best outcomes for healthcare professionals and patients alike.”

MUB Medical Solutions remains dedicated to innovation, research, and development to continuously improve the wound closure process. The patent grant in Indonesia is a testament to our relentless pursuit of excellence and our determination to provide state-of-the-art solutions to healthcare providers globally.

As we continue to expand our market presence in Indonesia and other strategic regions, we invite healthcare professionals, distributors, and potential partners to join us on this exciting journey. Together, we can make a significant impact on the wound closure industry and enhance patient care.

Stay connected with MUB Medical Solutions through our website and social media channels for the latest updates on our products, partnerships, and advancements in the field of wound closure.

Great news: MUB Medical joins Aleap.


MUB Medical Joins Aleap

Aleap for health startups

MUB Medical Joins Aleap in Oslo to Accelerate Commercialization

We are thrilled to announce that MUB Medical Solutions has joined Aleap, the largest incubator for health startups in the Nordics. This exciting partnership marks a significant milestone in our journey to revolutionize wound closure with our innovative product, Sutrips.

Aleap’s unique incubator model is designed to support ambitious entrepreneurs in building successful growth companies. With access to world-class competence, a vast network of industry experts, and funding opportunities, we are confident that our membership with Aleap will propel us forward on our mission.

Ubbat Ocak and Yasar Shaikh, CEOs of MUB Medical, express their enthusiasm about this collaboration. They firmly believe that joining Aleap will provide them with invaluable knowledge and connections that will expedite the process of bringing Sutrips to the market.

By becoming a part of Aleap, we are aligning ourselves with a vibrant ecosystem of like-minded innovators and industry leaders. This collaboration will undoubtedly foster an environment of collaboration, learning, and growth, enabling us to make a tangible impact in the field of wound closure.

We extend our heartfelt gratitude to Aleap for their belief in our vision and for providing us with this remarkable opportunity. We are excited to embark on this journey together and look forward to leveraging the resources and support offered by Aleap to bring Sutrips to healthcare providers and patients worldwide.

Stay tuned for more updates on our progress as we continue to push the boundaries of innovation and transform the landscape of wound closure.

Do you know that  MUB Medical Visited Center for Surgical Science at Zealand University Hospital last week?


Visiting Center For Surgical Science


MUB Medical Visits Center for Surgical Science at Zealand University Hospital

Last week, the team at MUB Medical had the privilege of visiting the prestigious Center for Surgical Science at Zealand University Hospital in Denmark. The visit proved to be an enlightening experience, as we engaged in fruitful discussions about our patented suturing technology and its potential to revolutionize the suturing process.

During our conversation, we received valuable feedback on our flagship product, Sutrips, which has the potential to significantly enhance the efficiency of suturing procedures. However, the benefits of our technology didn’t stop there. We were thrilled to discover that it holds promise for various other types of operations as well.

Building upon this positive interaction, we are excited to announce that we will be initiating collaborative work with the Center for Surgical Science to explore the development of a potential spin-off product based on our core patent. This collaboration opens up new avenues for innovation and reinforces our commitment to advancing medical technologies.

At MUB Medical, we understand the importance of engaging with end-users and gathering industry insights. It is through these interactions that we can refine our products to better meet the needs of healthcare professionals and patients alike. We are grateful for the opportunity to collaborate with esteemed institutions like the Center for Surgical Science and look forward to the possibilities that lie ahead.

Stay tuned for more updates as we continue our journey of transforming the field of wound closure and improving healthcare outcomes.

Explore Patent Issued in Australia.


Patent Issued in Australia



MUB Medical Secures Patent Approval for Sutrips in Australia

MUB Medical Solutions, a leading innovator in the field of wound closure, is thrilled to announce the approval and issuance of a patent for their groundbreaking product, Sutrips, in Australia.

The approval of the patent marks a significant milestone for MUB Medical, validating the uniqueness and inventive attributes of Sutrips. This achievement reinforces the company’s commitment to revolutionizing the field of wound closure and making a lasting impact on patient care worldwide.

Australia, with its thriving healthcare sector and commitment to innovation, is a strategic market for MUB Medical. The patent approval strengthens the company’s intellectual property rights and positions them for growth and market expansion in the region.

Sutrips, a state-of-the-art solution developed by MUB Medical, empowers healthcare professionals to efficiently and effectively close wounds. By enabling on-site wound closure, Sutrips eliminates the need for immediate patient transportation to medical facilities, resulting in improved outcomes and cost savings for healthcare providers.

“We are delighted to receive patent approval for Sutrips in Australia,” said Ubbat Ocak, Founder and Chief Technology Officer of MUB Medical Solutions. “This significant milestone reflects our dedication to innovation and our mission to enhance wound closure practices globally. We are excited to bring Sutrips to healthcare professionals in Australia, enabling them to deliver optimal care to patients.”

MUB Medical Solutions remains committed to protecting their intellectual property and ensuring that Sutrips continues to deliver groundbreaking solutions to the wound closure industry. The company’s ongoing efforts to secure patents in key strategic markets demonstrate their dedication to providing the best possible IP protection for their partners and customers.

With the Australian patent approval, MUB Medical is poised to expand its presence in the region, bringing the benefits of Sutrips to healthcare professionals and patients across the country.

Explore about Patent approved in South Africa.


Patent approved in South Africa

MUB Medical Secures Patent in South Africa, Advancing Accessible Wound Closure in Africa

MUB Medical Solutions, a leading innovator in the field of healthcare, is delighted to announce the successful granting of a patent for their revolutionary wound closure device, Sutrips, in South Africa. This patent approval marks a significant step forward in MUB Medical’s mission to improve access to effective wound closure solutions across the African continent.

South Africa, with its vast rural areas and limited access to medical facilities, faces unique challenges when it comes to wound care. Time, distance, and the cost of treatments are major considerations for both healthcare providers and patients. Recognizing this pressing need, MUB Medical developed Sutrips, which stands as one of the simplest and most efficient wound closure devices globally.

Sutrips empowers healthcare workers, including non-specialists, to confidently and securely close wounds on-location, eliminating the need for transportation to distant medical facilities. This breakthrough technology not only saves precious time but also reduces the financial burden associated with traditional wound closure methods.

By securing the patent in South Africa, MUB Medical paves the way for wider adoption of Sutrips throughout the African continent. The company remains committed to transforming wound closure by making it accessible and affordable to everyone, regardless of their geographical location.

The granting of the patent in South Africa reinforces MUB Medical’s dedication to improving healthcare outcomes and addressing the specific needs of communities in rural areas. This achievement sets the stage for expanding partnerships, collaborating with healthcare providers, and delivering high-quality wound closure solutions that positively impact patient care.

MUB Medical is excited to continue its journey of innovation and looks forward to working closely with healthcare professionals, stakeholders, and partners across Africa to revolutionize wound closure and improve the lives of patients everywhere.

Explore Patent Issued in Euroasia.